SB203580 Modulates p38 MAPK Signaling and Dengue Virus-Induced Liver Injury by Reducing MAPKAPK2, HSP27, and ATF2 Phosphorylation
Fig 5
SB203580 does not reduce DENV production in DENV-infected mice.
Mice were infected with 4 × 105 FFU/ml of DENV and treated with 2%DMSO alone or SB203580 in 2%DMSO. The uninfected control group was also treated with 2%DMSO. Seven days after infection, the liver tissues were collected, preserved in RNALater for the quantification of viral NS1, and in RPMI medium for an FFU assay. Total RNA was extracted to quantify viral NS1 with qRT–PCR. (A) Standard curve plotted from the Ct values for 10-fold serially diluted cDNA of known copy number (101–1010 copies). The dots represent the Ct values of each 10-fold dilution. (B) Viral NS1 copies in 1 μg of total RNA from 2%DMSO-treated (uninfected), 2%DMSO-treated DENV-infected, and SB203580-treated DENV-infected groups of mice (viral copies/μg). The supernatant was prepared from the liver tissue homogenates for the FFU assay. (C) Viral titers in the 2%DMSO-treated (uninfected), 2%DMSO-treated DENV-infected, and SB203580-treated DENV-infected groups of mice are expressed in FFU per milligram (FFU/mg). The results were obtained from six animals per group (n = 6). The data were analyzed with One-way ANOVA using GraphPad Prism 5 and are presented as means ± SEM. Asterisks show the level of significance (p < 0.05 is considered statistically significant).